IP Library Granted Patent US 11,275,086
Granted Patent B2
US 11,275,086 · App. 16/999,727 · Granted Mar 15, 2022

Use of amino acid sequences from

Inventors: Francesca Mariani (Rome, IT); Massimo Amicosante (Rome, IT); Vittorio Colizzi (Rome, IT); Cesare Saltini (Grottaferrata, IT)
Assignee: Cellestis Limited
G01N33/56972A61K38/10A61K38/164C07K7/08C07K14/35G01N33/5695G01N33/6866G01N2333/35G01N2333/57
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,275,086
App. No.
16/999,727
Granted
Mar 15, 2022
Kind
B2
Abstract

The present invention refers to the use of gene sequences or portions thereof characterized in that the same belong to the classes of in vitro and ex vivo induced, repressed or conserved genes in Mycobacterium tuberculosis currently infected human macrophages and to corresponding peptides or consensus peptides or proteins for the preparation of specific bio-markers for the diagnosis and prevention of active or latent disease.

Claims (9)

1. A method for detecting a Mycobacterium tuberculosis , infection in a test subject, comprising:

(a) incubating in vitro a blood sample or a lavage sample that comprises lymphocytes from the test subject with at least one isolated protein or peptide that comprises at least one Mycobacterium tuberculosis T-cell epitope, said isolated protein or peptide being selected from:

SEQ ID NO:1 (Rv0023), SEQ ID NOS:2-3 (Rv0182c) and SEQ ID NOS: 4-5 (Rv0290),

wherein said step of incubating is for a time and under conditions sufficient to stimulate the lymphocytes to produce an effector molecule; and

(b) detecting a test level of the effector molecule, wherein detection of a test level that is higher than a control level that is detected following incubation of control lymphocytes from a healthy control subject, indicates that the test subject is infected with, or has been previously exposed to, the Mycobacterium tuberculosis.

2. The method of claim 1 wherein

the subject is a human or non-human animal and either or both of:

(1) the isolated protein or peptide consists of an amino acid sequence selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5,

(2) in the step of incubating there is present one or more Mycobacterium protein, selected from ESAT6, CFP10, TB7.7 and PPD, and the detected test level of the effector molecule is greater than a detectable effector molecule level that can be produced by said lymphocytes incubated only with said one or more Mycobacterium protein selected from ESAT6, CFP10, TB7.7 and PPD.

Assignments (4)
PATENT TRANSFER AGREEMENT Recorded Mar 26, 2025
From: QIAGEN NORTH AMERICAN HOLDINGS, INC.
To: QIAGEN SCIENCES LLC
Reel/Frame 070636/0331 →
RESOLUTION OF JOINT AND SEVERAL LIQUIDITATORS Recorded Mar 25, 2025
From: QIAGEN AUSTRALIA HOLDING PTY LTD
To: QIAGEN NORTH AMERICAN HOLDINGS INC.
Reel/Frame 070619/0276 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 21, 2025
From: CELLESTIS PTY. LTD.
To: QIAGEN AUSTRALIA HOLDING PTY LTD.
Reel/Frame 070587/0530 →
CHANGE OF NAME Recorded Mar 21, 2025
From: CELLESTIS LIMITED
To: CELLESTIS PTY LTD
Reel/Frame 070588/0275 →
Priority Claims (1)
IT RM2010A000411 · Jul 23, 2010 · national
Continuity (5)
Division 16557536 · Aug 30, 2019
Division 15793746 · Oct 25, 2017
Division 14798241 · Jul 13, 2015
Division 13811906
Related Publication 20200386755A1 · Dec 10, 2020